These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19220256)

  • 21. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
    McHugh LA; Kriajevska M; Mellon JK; Griffiths TR
    Urology; 2007 Feb; 69(2):390-4. PubMed ID: 17320695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
    Troiani T; Lockerbie O; Morrow M; Ciardiello F; Eckhardt SG
    Mol Cancer Ther; 2006 Jul; 5(7):1883-94. PubMed ID: 16891475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
    Morelli MP; Cascone T; Troiani T; De Vita F; Orditura M; Laus G; Eckhardt SG; Pepe S; Tortora G; Ciardiello F
    Ann Oncol; 2005 May; 16 Suppl 4():iv61-68. PubMed ID: 15923432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
    Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
    Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
    Hanrahan EO; Ryan AJ; Mann H; Kennedy SJ; Langmuir P; Natale RB; Herbst RS; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3600-9. PubMed ID: 19447868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.
    Azzariti A; Porcelli L; Xu JM; Simone GM; Paradiso A
    World J Gastroenterol; 2006 Aug; 12(32):5140-7. PubMed ID: 16937523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
    Yoshikawa D; Ojima H; Kokubu A; Ochiya T; Kasai S; Hirohashi S; Shibata T
    Br J Cancer; 2009 Apr; 100(8):1257-66. PubMed ID: 19319137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
    Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
    Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
    Brave SR; Odedra R; James NH; Smith NR; Marshall GB; Acheson KL; Baker D; Howard Z; Jackson L; Ratcliffe K; Wainwright A; Lovick SC; Hickinson DM; Wilkinson RW; Barry ST; Speake G; Ryan AJ
    Int J Oncol; 2011 Jul; 39(1):271-8. PubMed ID: 21537841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
    Shrader M; Pino MS; Brown G; Black P; Adam L; Bar-Eli M; Dinney CP; McConkey DJ
    Mol Cancer Ther; 2007 Jan; 6(1):277-85. PubMed ID: 17237287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
    Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
    Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
    Kassouf W; Brown GA; Black PC; Fisher MB; Inamoto T; Luongo T; Gallagher D; Bar-Eli M; McConkey DJ; Adam L; Dinney CP
    J Urol; 2008 Sep; 180(3):1146-53. PubMed ID: 18639280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
    Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
    J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
    Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.
    Gu WG; Huang Y; Yuan ZY; Peng RJ; Luo HT; He ZR; Wang SS
    Asian Pac J Cancer Prev; 2013; 14(3):1787-90. PubMed ID: 23679274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.
    Meemanage M; Spender LC; Collinson D; Iannetta J; Challapalli P; Turbitt J; Clark C; Baxter M; Murray G; Walsh S; Miedzybrodzka Z; Petty RD
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):361-377. PubMed ID: 33169187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.
    Klass CM; Choe MS; Hurwitz SJ; Tighiouart M; Zhang X; Chen ZG; Shin DM
    Head Neck; 2009 Oct; 31(10):1263-73. PubMed ID: 19399750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.